Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6296 patients treated with thrombolytic agents

American Heart Journal

Volumn 137, Issue 3, 1999, Pages 443-452

  Villella, Massimo ^a   Villella, Alessandro ^b   Barlera, Simona ^b   Franzosi, Maria Grazia ^b   Maggioni, Aldo P ^b  

^a GISSI Coordinating Centre   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BICYCLE ERGOMETRY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE TEST; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTOLIC BLOOD PRESSURE; TREADMILL ERGOMETRY; WORK CAPACITY;

EID: 0033014271     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70490-4     Document Type: Article

References (24)

1. 1. Gobel FL, Nordstrom LA, Nelson RR, et al. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation 1978;57:549-56.
2. 2. Nelson RR, Gobel FL, Jorgensen C, et al. Hemodynamic predictors of myocardial oxygen consumption during static and dynamic exercise. Circulation 1974;50:1179-89.
3. 3. Kitamura K, Jorgensen CR, Gobel FL, et al. Hemodynamic correlates of myocardial oxygen consumption during upright exercise. J Appl Physiol 1972;32:516-22.
4. 4. Irving JB, Bruce RA, DeRouen TA. Variations in and significance of systolic pressure during maximal exercise testing. Am J Cardiol 1977;39:841-8.
5. 5. Saunamäki KI, Andersen JD. Early exercise test in the assessment of long-term prognosis after acute myocardial infarction. Acta Med Scand 1981;209:185-91.
6. 6. Saunamäki KI, Andersen JD. Early exercise test vs clinical parameters in the long-term prognostic management after myocardial infarction. Acta Med Scand 1982;212:47-52.
7. 7. Saunamäki KI, Andersen JD. Post-myocardial infarction exercise testing: clinical significance of a left ventricular function index and ventricular arrhythmias. Acta Med Scand 1985;218:271-8.
8. 8. Madsen EB, Gilpin E. Prognostic value of exercise test variables after myocardial infarction. J Cardiac Rehabil 1983;3:481-8.
9. 9. Lavie CJ, Gibbsons RJ, Zinsmeister AR, et al. Interpreting results of exercise studies after acute myocardial infarction altered by thrombolytic therapy, coronary angioplasty or bypass. Am J Cardiol 1991;67:116-20.
10. 10. Villella A, Maggioni AP, Villella M, et al. Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 database. Lancet 1995;346:523-9.
11. 11. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
12. 12. Carù B, Rulli V, Spadaccini F, et al. Criteri di guida per l'esecuzione di tests ergometric: Protocollo del Gruppo Italiano per la Valutazione Funzionale e la Riabilitazione del Cardiopatico. G Ital Cardiol 1983;13:276-82.
13. 13. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [Series B] 1972;34:187-220.
14. 14. Marubini E, Valsecchi MG. Analyzing survival data from clinical trials and observational studies. Chichester: John Wiley & Sons; 1995. p 223-39.
15. 15. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978; 8:283-98.
16. 16. Fleiss JI. Statistical methods for rates and proportions. New York: John Wiley & Sons; 1981. p 218-21.
17. 17. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989. p 135-75.
18. 18. Volpi A, De Vita C, Franzosi MG, et al. Determinants of 6-month mortality in survivors of myocardial infarction after thrombolysis: results of GISSI-2 data base. Circulation 1993;88:416-29.
19. 19. Svendsen JH, Madsen JK, Saunamäki KI, et al. Effect of thrombolytic therapy on exercise during early recovery from acute myocardial infarction: a placebo controlled study. Eur Heart J 1992;13:33-8.
20. 20. Stevenson R, Umachandran V, Ranjadaylan K. Reassessment of treadmill stress testing for risk stratification in patients with acute myocardial infarction treated by thrombolysis. Eur Heart J 1993;70:415-20.
21. 21. Crawford MH. Exercise-induced myocardial ischemia: importance of coronary blood flow. Circulation 1991;84:424-5.
22. 22. Frishman WH, Pepine CJ, Weiss R, et al, for the Zatebradine Study Group. The addition of a direct sinus node inhibitor (zatebradine) provides no greater exercise tolerance benefit to patients with angina pectoris treated with extended release nifedipine: results of a multicenter, randomized, double-blind, placebo-controlled, parallel group study. J Am Coll Cardiol 1995;26:305-12.
23. 23. Glasser SP, Michie D, Thadani U, et al, Zatebradine Investigators I. Selective reduction of heart rate with the sinus node inhibitor zatebradine (ULFS 49) does not lead to the expected improvements in exercise duration in patients with angina pectoris [abstract]. J Am Coll Cardiol 1995;25(2):127A.
24. 24. Frishman WH, Gabor R, Pepine C. Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor. Am Heart J 1996;131:204-10.